#Avatan medicine registration
#Avatan medicine trial

Initial reports indicate a similar decline of non‐COVID‐19 trials in Europe and the US in 2020, 7, 8 and a nominal reduction in new trials internationally in 2021. Data from the first 11 pandemic months suggest a decline in the number of Australian trials starting in 2020 (17% fewer than in 2019).

#Avatan medicine trial

The impact of the COVID‐19 pandemic on trial activity is complex, with further in‐depth analysis desirable. Streamlining of approval processes for trial start‐up is anticipated through the proposed National One Stop Shop platform. The implementation of the Australian Commission on Safety and Quality in Health Care National Clinical Trials Governance Framework 5 in public and private health services is expected to address this need. An even further improvement of Australia's trial activity could be achieved by better integration of trial research in routine health care. Few countries have more activity than Australia, including Belgium and Denmark. These trials planned to recruit a total of 8.7 million people from 2006 to 2020, albeit this includes participants in Australia and internationally.Īustralian trial activity (number of trials per capita) compares favourably with other OECD countries, with more activity in Australia than in France, Germany, and the United States ( Box 2). This includes Australia‐only (12 775 trials, 69%) and multinational trials (5678 trials, 31%). From 2006 to 2020, over 18 000 trials recruiting participants in Australia were registered, 40% of those in the period 2016–2020. Australian trial activity compares favourably internationallyĪustralia has a highly active trials community, exemplified by the number, breadth and sponsorship of trials ( Box 1). 2 The methods are detailed in the Supporting Information.

#Avatan medicine registration

Data are sourced from the Australian New Zealand Clinical Trials Registry (ANZCTR) that captures over 95% of registered trials occurring in Australia through trial registration and data feed from. 2 We describe characteristics and trends of Australian trials, make international comparisons, and outline areas for further enquiry or support. In this perspective, we present key findings from a comprehensive report of Australian clinical trial activity from 2006 to 2020. 1 Trial results can drive change by informing best practice in health care and future research. There is a strong history of Australian trials addressing important health care questions by covering a range of diseases, patient groups, prevention and treatment modalities.

Statistics, epidemiology and research designĮxamining the clinical trials landscape in Australia is important for governance and to expand knowledge about trial activity to health professionals, the public and funders.